What is Eyevensys?
Eyevensys is a privately held biotechnology company headquartered in Paris, France, established in 2008. The company is dedicated to developing innovative technology aimed at enabling the sustained intraocular production of therapeutic proteins. This technology is designed to address a broad spectrum of ophthalmic diseases, positioning Eyevensys at the forefront of advanced eye care solutions. The company's clinical-stage development signifies a critical phase in its journey towards bringing novel treatments to patients.
How much funding has Eyevensys raised?
Eyevensys has raised a total of $43.7M across 3 funding rounds:
Series A
$1.7M
Series B
$30M
Series B
$12M
Series A (2016): $1.7M with participation from Pontifax
Series B (2020): $30M, investors not publicly disclosed
Series B (2021): $12M supported by Korea Investment Holdings
Key Investors in Eyevensys
Pontifax
Pontifax Venture Capital is a prominent venture capital firm specializing in groundbreaking innovations within the life sciences sector. They focus on transformative healthcare technologies across all development stages, actively identifying and nurturing disruptive ideas from research centers. Pontifax provides hands-on guidance and networking to maximize the success of its portfolio companies, with a particular emphasis on clinical-stage ventures.
Korea Investment Holdings
Korea Investment Holdings is a major financial firm in Korea, formed through the merger of KITC and Dongwon Securities. It is a leader in asset management, securities brokerage, and investment banking, with a significant role in the development of the Korean capital market. The firm has a strong track record in initial public offerings and managing investment trust products.
What's next for Eyevensys?
The recent major strategic investment indicates a strong vote of confidence in Eyevensys's technology and its potential to revolutionize the treatment of ophthalmic conditions. This influx of capital, part of the overall $43.7M raised, is expected to accelerate the company's research and development pipeline, potentially leading to clinical trials and eventual market entry. The strategic nature of the investment suggests a focus on long-term growth and market penetration, likely involving partnerships and further validation of its therapeutic protein production platform.
See full Eyevensys company page
